Past Speakers
Mostafa Alabed, Health Economics Analyst, Evaluation and Impact Measurement Unit, Ministry Of Health - Kingdom Of Saudi Arabia
David Alderson, Director, Cogentia Healthcare Consulting
Ines Alves, President, ANDO Portugal
Francis Arickx, Head Of The Directorate Reimbursement Of Medicines And Pharmaceutical Policy, Riziv-Inami
Nadeem Ashraf, Head of CardioMetabolism for Medical Affairs, UK & Ireland, Boehringer Ingelheim
Indranil Bagchi, Senior Vice President And Head Of Global Value And Access, Novartis
Alex Bastian, Vice President, Value And Market Access, Galapagos NV
Antje Behring, Head of Pharmaceuticals Department, G-BA
Tomer Ben Zaken, Pricing And Alliance Manager, Takeda
Karsten Berndt, International HTA Lead, Myriad Genetics GmbH
Jennifer Cain Birkmose, Vice President, Global Head Of Patient Access And Community Engagement, Swedish Orphan Biovitrum
Jesper Bjerggren, Senior Market Access Manager, Teva Denmark
Maria Alejandra Blanc, Director - Regulatory Affairs – Region South America, AbbVie
Nadia Bodkin, Founder, Rare Advocacy Movement
Axel Boehnke, Director Market Access EU North, PTC Therapeutics
Luc Boileau, Chairman And Chief Executive Officer, INESSS
Thomas Bols, Head of Government Affairs and Public Policy, EMEA & APAC, PTC Therapeutics
Luciene Fontes Schluckebier Bonan, Innovation and HTA General Coordinator, Ministry of Health - Brazil
Meindert Boysen, Deputy Chief Executive and Director of the Centre for Health Technology Evaluation, National Institute for Health and Care Excellence
Hassan Bruneo, Head of Market Access, Pricing & Policy CEMEA, Alnylam Switzerland Gmbh
Anna Bucsics, Project Advisor, Mechanism of Coordinated Access to orphan medicinal products (MoCA)
Sandro Cesaro-Tadic, Head Strategic Product Pricing, Roche
Anjan Chatterjee, Senior Vice President - Global Head, Medical Affairs, Insmed Incorporated
Helene Chevrou-Severac, HEOR Director, Alexion
Mouna Jameleddine Chtioui, Director of the Health Technology Assessment Department, INEAS - TUNISIA
Ali Ciger, Commercial Director, Pain, Pfizer
Cliff Cox, Director, Evidencia
Mike Crosher, Managing Director, Chugai Pharma UK
Alan Crowther, General Manager, Global Pricing, Access and Digital Solutions, EVERSANA
Omar Dabbous, Vice President, Global Heor and Rwe, AveXis Inc
Aletta de Beer, Product Owner Intensive Care, Pacmed
Charles-Etienne de Cidrac, Director Of Health Insurance, AXA
Erwin De Cock, Executive Director, Real World and Late Phase, Syneos Health, Syneos Health
Michele de Guise, Scientific Vice-President, INESSS
Carla Deakin, Programme Director - Commercial And Managed Access, NICE
Kate Dion, Value Communications Lead, 3D Communications
Valentin Dodonov, Head of Market Access, BIOCAD
Filippo Drago, Full Professor of Clinical Pharmacology, University of Catania
Gilles Ducorroy, Head of RWE Services, Novartis
Dominik Dziurda, Head Of Health Services Division, AOTMiT
Mercedes Echauri, Head of Pricing, Value and Access, Europe & Canada, Takeda
Jaime Espin, Professor, Andalusian School Of Public Health
Gina Ewy, Head Of Global Market Access, Hansa Biopharma
Onno Faber, Co-Founder & CEO, Rarebase
Valerie Faillat, Head of Sanofi Espoir Foundation, sanofi
Douglas Foerster, Former Head Market Access, Santhera Pharmaceuticals
Isabelle Ganache, Director of Bureau for Methodologies and Ethics, INESSS
Benjamin Gannon, Vice President International Access, Policy And Advocacy, Myriad genetics
Sandra Garitonandía, LS Industry Principal EMEA, Vistex
Josie Godfrey, Director, JG Zebra Consulting
Wim Goettsch, Special Hta-Advisor, Zorginstituut
Alfredo Gracia, Market Access Manager Spain, Baxter
Sylvie Greneche, Global Head of Market Access, General Medicines, Sanofi
Laura Guarga, Consultant of Pharmacoeconomic Department, CatSalut
Diego Guarin, Regional Market Access Lead , Latin America, Merck
Clare Hague, Therapy Area Market Access Lead, Hematology, Janssen Pharmaceutical
Danielle Haller, Rare Disease Experience Expert, Rare Advocacy Movement
Bernard Hamelin, Former Global Head Of Medical Evidence Generation, Sanofi
Zahraa Hassan, Pharmacoeconomics Unit, Egyptian drug authority
Suzy Heafield, Head of Medicines Value, NHS England and Improvement
Birgit Holz, Global Head of Contracting Innovation, Sanofi
Giorgio Iotti, Head Of Program Leadership And Control, Rare Disease Unit, Chiesi Farmaceutici SpA
Dawn Ireland, President, CDH International
Ulrike Jacobi, Head Of External Affairs And Market Access, Amgen
Saira Jan, Vice-President & Chief Pharmacy Officer, Blue Cross Blue Shield of New Jersey
Elizabeth Johnson, Director of Product Management, RxLightning Inc.
Rosemary Jose, Senior Director, Strategic Market Access, Open Health
Navin Joshi, Global Head of Pricing and Access Capabilities, GlaxoSmithKline
Marcela Junqueira, Oncology Market Access Director - Latin America, Janssen Pharmaceutical
Madhusudan Kabra, Director, Evidence Generation, Otsuka Pharmaceutical
Gomathi Kaliappan, Health Systems Strategy Leader - Global Access, Roche
Lisette Kaskens, Senior Global Market Access Manager, Advanced Accelerator Applications
Jolanda Koenders, Head Of Patient Value And Access, Takeda
Adam Kundzewicz, Global Head of Strategic Market Access Initiatives, Boehringer Ingelheim
Oliver Leatham, VP, Global Head of Commercial Strategy and EU Value & Access, Certara
Jost Leemhuis, Head Of Safety Science, Roche
Friedhelm Leverkus, Director Health Technology Assessment And Outcomes Research, Pfizer
Gavin Lewis, Vice President For Value, Access And Policy, Amgen
Nanxin (Nick) Li, Senior Director and Head, Health Economics and Outcomes Research (HEOR), uniQure
Edmund Lim, Executive Director, We CARE Journey
Catarina Lopes Pereira, Global Market Access Manager, Medac
Chris Lundy, Community-based Experience Professional, Rare Advocacy Movement
Elena Lungu, Manager Of Policy Development, Government of Canada
Richard Macaulay, Vice President, Global Pricing and Market Access, PRECISIONadvisors
Alastair Macdonald, Senior Vice President Of Real World And Late Phase, Syneos Health
Mark Macgregor, Medical Director and Chair, New Drugs Committee, Scottish Medicines Consortium, Golden Jubilee National Hospital
Andrea Mantovani, Former Market Access Executive, independent
Marco Marchetti, Director Of The National Center For Health Technology Assessment, Istituto Superiore di Sanita
Caroline Mathie, Vice President, Rare Diseases, The Planning Shop International Ltd
Dan McLean, Senior Manager, Pan-Canadian Pharmaceutical Alliance Office
Christopher Missling, President, Anavex Life Sciences
Erin Mistry, SVP, Head of Payer Strategy, Gov’t Affairs and Trade Relations, CorMedix Inc
Vladimir Mladov, HTA Manager, BIOCAD
Paolo Morgese, EU Director Market Access & Member Relations, Alliance for Regenerative Medicine
Thomas Mueller, Head Of Directorate General 1 - Drugs, Medical Devices, Biotechnology, Federal Ministry of Health Germany
Michael Muller, Head Of Market Access, Western Europe, Sun Pharma
Diane Munch, Head of Global Pricing, Patient & Health Impact, Pfizer
Nuriya Musina, Head Of Development, Federal State Budgetary Institution, The Center For Healthcare Quality Assessme, Ministry of Health Russian Federation
Alexander Natz, Secretary General, European Confederation of Pharmaceutical Entrepreneurs (Belgium)
Enkeleida Nikai, Head Of Real World Evidence, Senior Director At Janssen Europe, Middle East And Africa (Emea), Janssen Pharmaceutical
Mark Nuijten, Chief Executive Officer, A2M - Minerva
Pier Paolo Olimpieri, Data Analyst Coordinator, Monitoring Registries Office, AIFA
Melvin Olson, Global Head Rwd Strategy And Innovation, Novartis Pharma
Amer Omar, Head of Access & Reimbursement EMEA Neuroscience - Rare & Genetic Disease, Lupin
Robert Orzechowski, Chief Operating Officer, Lancaster Cancer Centre
Mario Ouwens, Group Director Medical & Payer Evidence Statistics, Astra Zeneca
Elena Panitti, Global Rwe Capability Building Lead, Novartis
Detlev Parow, Head Pharmaceutical Department, DAK-Gesundheit
Diogo Teixeira Pereira, Policy Analyst - Office for International Relations and Development, Infarmed
Ed Pezalla, Former Vice President, National Medical Director For Pharmaceutical Policy And Strategy, Aetna; a CVS Pharmacy Health Company
Andres Pichon Riviere, Executive Director And Director Of Health Technology Assessment And Economic Evaluations, I.E.C.S.
Lara Pippo, Head Of Market Access, CSL Behring
Ana Plata, Global Head of Pricing, UCB
Adam Plich, Managing Director, Plich Advisory
Mary Lynne Van Poelgeest-Pomfret, President, President of the World Federation for Incontinence and Pelvic Pain - WFIP
Angelina Irizari Policarpio, Head of HEOR and RWE Field Communications Team, Eisai
Nadia Quignot, Director, Decision Analytics & Real World Evidence, Certara
Marco Rauland, Vice President Global Market Access & Pricing Strategic Planning, Merck Group
Laurene Redding, Head, Value, Access & Policy, BeiGene
Vijay Reddy, Senior Director - Global Market Access Strategy - Biologics, Biocon Biologics
Isabell Remus, Head Biosimilars & Specialty Business, Europe, Sandoz
Andreia Ribeiro, Director, Lifescience Dynamics Ltd
Trevor Richter, Director, Pharmaceutical Reviews, CADTH
Kevin Rieger, Head Of Public And Governmental Affairs Dach, Ipsen Pharma Gmbh
Shirin Rizzardo, Director of Specialty Medicines, Ministry of Health, British Columbia
Kay-Diene Robinson, rare360 DEI Expert, Rare Advocacy Movement
Juan Roman, Vice President, Global Market Access, HEOR and Pricing, Krystal Biotech
Igor Rudychev, Vice President, Enterprise Analytics, Horizon Therapeutics
Asmaa Saad, Head of the Pharmacoeconomics unit, Egyptian drug authority
Ryan Saadi, CEO, Tevogen Bio
Marcelo Sal, Head of Market Access and Pricing, South Cone of South America, PTC Therapeutics
Gustavo Saraiva Dos Anjos, Global Market Access Director For Biologics, GlaxoSmithKline
Marie Theres Schmidt, Director Market Access And Government Affairs, Edwards Lifesciences
Gundula Schneidewind, Head Ethics And Compliance, Europe And Canada, Takeda
Michael Schroter, Partner, VIOPAS Partners
Martin Schuchardt, Global Market Access Lead, Almirall
Ayman Semaan, Head of Market Access, Algorithm
Maja Sercic, Policy & Science Manager, Medicines for Europe
Alexis Serlin, Head, Asia Cluster, Novartis
Jonas Sertorio, Innovation and HTA Consultant, Ministry of Health - Brazil
Rita Shorjian, Business Unit Director – Gulf Countries, Specialty, HCV & Oncology, AbbVie
Heather Shorten, Executive Director, Pompe Alliance
Matt Slabbert, Global Head, Value & Access Policy, Bayer Pharmaceuticals
Valeriia Sokolova, Health Economics Manager, BIOCAD
Daniel Sperber, Senior Economist, Pan-Canadian Pharmaceutical Alliance Office
Deanna Steinle, Rare Disease Experience Expert, Rare Advocacy Movement
Giovanni Tafuri, Director, International Pricing & Reimbursement and Policy Strategy, Apellis Pharmaceuticals
Bertrand Tardivel, General Manager, Frehel/ContrAST
Samuel Taylor, Emerging Markets Strategic Pricing Lead, Pfizer
Chris Teale, Vice President Market Access, Ipsos MORI UK Ltd
Daria Tolkacheva, Head of Health Economics, BIOCAD
Amardeep Udeshi, Partner, EVERSANA
Sheela Upadhyaya, Accelerated Access Collaborative Relationship & Delivery Lead & HST Specialist, National Institute for Health and Care Excellence
Inneke Van De Vijver, Strategic Advisor - Reimbursement Pharmaceuticals, R.I.Z.I.V. I.N.A.M.I. National Health Insurance Agency
Erik Van Den Berg, Chief Executive Officer, A.M. Pharma
Bart Van Den Daele, External Affairs Director, Gilead Sciences
Goedele Van Haasteren, Hta Specialist, Swiss Federal Office of Public Health
Kärt Veliste, Chief Specialist at Department of Medicines and Medical Devices, Haigekassa Estonia
David Watson, Executive Director, Economic, Health and Commercial Policy, ABPI
Anne Willemsen, Senior Project Manager, Joint Production Co-Lead Partner – Pharmaceuticals, Zorginstituut Nederland / EUnetHTA
Lynn Wilson, Vice President, Myositis Support and Understanding
Natasa Zibelnik, Global Head Of Market Access, EUSA Pharma
Peter Zimmermann, Sr. Director of Professional Services, Model N
Fabrizio Zucca, Director Market Access Dach, Intercept Pharmaceuticals Inc
Get Involved
To sponsor or exhibit:
Edmond Rama
+44 (0)207 092 1052
edmond.rama@terrapinn.com
To speak:
Chris Shanks
+44 (0)207 092 1151
chris.shanks@terrapinn.com
Organiser
